Multiple anthelmintic resistance of *Haemonchus contortus*, including a case of moxidectin resistance, in a Dutch sheep flock


Benzimidazole resistance in sheep was first described in 1964 (Drudge and others 1964). Nowadays, multiple anthelmintic resistance is of major concern for the sheep and goat industry (Sargison 2012). In Europe, resistance to moxidectin (MOX) has been described in Germany in *Haemonchus contortus* (Scheuerle and others 2009), in the UK in *Teladorsagia circumcincta* (Wilson and Sargison 2007, Sargison and others 2010), and recently to long-acting injectable MOX in north-western Spain (Martínez-Valladares and others 2013), and is not as common as resistance to ivermectin (IVM) and doramectin (DRM) (Maingi and others 1997, Ambrosini 2000, Sargison and others 2001, Clemans and others 2006, Borgsteede and others 2007).

On a Dutch sheep farm, MOX resistance was suspected, and a study was conducted aiming (1) to investigate this suspected case, (2) to simultaneously test the efficacy of DRM, monepantel (MPL), fenbendazole (FBZ) and levamisole/triclabendazole (LEV/TCBZ) and (3) to identify the genus and species of nematodes before and after treatment. Group 2–6 were treated with MOX (Cydectin 0.1 per cent Oral Solution for Sheep, Zoetis BV) directly after lambing, and with DRM (Dectomax Solution for Injection, Zoetis BV) six weeks prior to breeding. Lambs were treated in spring first with oxendazole (Bovex Oral Suspension, Chanelle), and subsequently every four to five weeks alternately with DRM and MOX. In August 2012, lambs were in poor condition and, after treatment with MOX, high strongyle-type egg counts were found in pooled faecal samples.

During late summer, 6 groups of 10 lambs were randomly selected out of a flock of 100 crossbred Texel lambs, and were weighted, marked and individually identified. On day 0 and day 10, individual faecal samples were collected. Lambs from group 1 remained as untreated controls. Group 2–6 were treated with MOX (Cydectin 0.1 per cent Oral Solution for Sheep, 0.2 mg/kg bodyweight, Zoetis BV), DRM (Dectomax Solution for Injection, 0.2 mg/kg bodyweight, Zoetis BV), MPL (Zolvix, 2.5 per cent Oral Solution for Sheep, 2.5 mg/kg bodyweight, Novartis Animal Health), FBZ (Panacur 2.5 per cent Oral Suspension for Sheep, 5 mg/kg bodyweight, MSD Animal Health), LEV/TCBZ (Endex 8.5 per cent Oral Suspension for Sheep, 7.5 mg LEV/kg bodyweight, Novartis Animal Health), respectively, at the manufacturer’s recommended dose rate.

A faecal egg count reduction test (FECRT) was carried out according to the method of the World Association for the Advancement of Veterinary Parasitology (WAAVP) (Coles and others 1992). Faecal egg counts (FEC) were performed using a modified McMaster method with a sensitivity of 17 eggs per gram (EPG). The percentage reduction was calculated according to the following formula: 

$$\text{Efficacy} = 100 \times \left(1 - \frac{\text{ arithmetic mean EPG of the treated group}}{\text{ arithmetic mean EPG of the control group}}\right)$$

Results of coprocultures are also given in Table 1. At day 0, faecal samples of 59 out of 60 lambs were positive for strongyle-type eggs. At day 10, one DRM-treated lamb was presented with severe pneumonia and no faeces could be collected. At day 10, no strongyle-type eggs were seen in samples from the MPL and LEV/TCBZ groups. In all other samples, strongyle-type eggs could be detected. Calculated efficacies indicated that resistance was present to MOX, DRM and FBZ, while the worm population was fully susceptible susceptible to MPL and LEV/TCBZ.

Results of coprocultures are also given in Table 1. At day 0, all larvae (n=100) in the control group were identified as *H. contortus*. In the MOX group, DRM group, MPL group, FBZ group and the LEV/TCBZ group, the percentage *H. contortus* was 97, 95, 94, 97 and 98 per cent, respectively. All remaining larvae were identified as *Teladorsagia/Trichostongylus* species.

At day 10 again, all larvae in the control group (n=100) were identified as *H. contortus*. In the MOX group, DRM group and FBZ group, the percentage *H. contortus* was 99, 100, and 98 per cent, respectively. In the LEV/TCBZ group, five larvae were detected, and one was identified as *H. contortus*. All remaining larvae were identified as *Teladorsagia/Trichostongylus* species. No larvae were detected in the MPL group.

Multiple anthelmintic resistance is a worldwide threat to the small ruminant industry. Although MOX resistance has been described before in Europe (Wilson and Sargison 2007, Scheuerle and others 2009, Sargison and others 2010, Martinez-Valladares and others 2013), this study confirmed a case of *H. contortus* resistance to milbemycins and avermectins, MOX and DRM, in a sheep flock in Europe. Also, resistance to FBZ was found in this flock. Outside Europe,
resistance to MOX is much more common (Watson and others 1996, Wooster and others 2001, Ranjan and others 2002, Chandrawathani and others 2003, Hughes and others 2004, Almeida and others 2010). In The Netherlands, resistance of *H. contortus* to LEV and MPL has not been found.

On this farm, MOX treatments during quarantine and around lambing, and repeated treatments of lambs with DRM and MOX before turning the animals on low contaminated pastures possibly offered resistant alleles a survival advantage, and established a heavily preselected population. Limited use of anthelmintics and correct anthelmintic dose rates, combined with targeted grazing management, are important features of modern parasite control, trying to prevent selection for resistance especially when the proportion of susceptible nematodes exposed to the anthelmintic compared with that on pasture is high at the time of treatment. These control measures are even more important taking into account that long-term reversion to susceptibility is unusual or, in all probability, does not occur within flocks (Sargison 2012).

### Acknowledgements

Monitoring of Small Ruminant Health is financially supported by the Dutch Ministry of Economic Affairs (EZ) and the Product Board for Livestock and Meat (PVV). We would like to thank our colleagues, Coen Hegeman and Edwin Tuller, for performing the FEC and preparing the composite larval culture. Additionally, we would like to thank the farmers for their cooperation. Finally, we would like to thank David Bartram and Thomas Geurden for their useful comments on the manuscript.

### Contributors

All authors were involved in the study design. RVDB, UM, BDP sampled the animals. DOCVD and HMBV were involved in the laboratory analysis. UM and HMBV did the data analysis. RVDB initially wrote the manuscript. All other authors gave their remarks on the manuscript.

### Funding

This study was partly funded by Zoetis BV.

### Competing interests

At the time of this study, D P D was a paid employee of Zoetis BV.

### Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

## References


Multiple anthelmintic resistance of *Haemonchus contortus*, including a case of moxidectin resistance, in a Dutch sheep flock


*Veterinary Record* 2013 173: 552 originally published online November 6, 2013
doi: 10.1136/vr.101700

Updated information and services can be found at:
http://veterinaryrecord.bmj.com/content/173/22/552.1

These include:

**References**
This article cites 20 articles, 3 of which you can access for free at:
http://veterinaryrecord.bmj.com/content/173/22/552.1#BIBL

**Open Access**
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

Open access (110)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/